Sanofi delivered Q4 2025 adjusted EPS of €1.53 on revenue of €11.3 billion, driven by a 32.2% increase in Dupixent sales to €4.2 billion. Vaccine revenue declined 2.5% to €2.0 billion as broader market volatility weighed on performance.

The board approved a €1.0 billion share buyback program for 2026, aiming to enhance shareholder returns and optimize capital structure. Execution details, including timing and volume, will be announced later in the fiscal year.

Management projects at least five years of profitable growth, underpinned by robust pipeline advancement and increased R&D spending. CEO projections emphasize the need for new products to sustain momentum beyond Dupixent’s market maturity.